Aparito - a wholly owned subsidiary of Eli Lilly and Company

New paper! 📔 Demonstrating the feasibility of using a smartphone app for home-based video assessments of gait and balance in people living with #ParkinsonsDisease 📱👟 The #vTUG could enhance patient engagement and provide more real world data for future trials. Discover more 👇 https://hubs.li/Q02Sj_1d0 #vCOA

Excited to announce that Dr. Elin Haf Davies will be speaking on the “Investment for TechBio Companies” panel at TechBio UK! Learn more and register here 👇 https://hubs.li/Q02Sj_170 #TechBioUK #Biotech

It's #InternationalGaucherDay and to mark #IGD we revisit GaRDIAN, a patient-led, patient-owned registry for neuronopathic #Gaucher disease (nGD), a rare condition that has a significant impact on patients and caregivers. nGD has minimal natural history (combined with small patient numbers and huge heterogeneity within the same genotype) so GaRDIAN intends to bridge the many gaps in the understanding of nGD and align with regulatory frameworks on real-world data needs. Read the paper here 👇 https://hubs.li/Q02Rsy1G0

On #AtaxiaAwarenessDay we share our work to digitise the Scale for the Assessment and Rating of Ataxia (SARA) into SARAhome to measure the impact of #ataxia on patients’ everyday lives. 📱 This approach enabled us to develop a video #eCOA where daily assessments provide a more meaningful measure of the severity of ataxia than a conventional snapshot visit conducted once a year. 📈 Discover more about SARAhome in our white paper here 📚 https://hubs.li/Q02QLt920 #vCOA

On #WorldDuchenneAwarenessDay, Duchenne UK and Aparito celebrate our decentralised validation study using home-based video assessments to track limb function in patients with Duchenne muscular dystrophy (#DMD). 📚 DMDhome uses video capture and computer vision analysis to measure limb function in Duchenne muscular dystrophy and the study intends to validate the DMDhome platform to improve the evaluation of new treatments. Recruitment is now ongoing, offering participants the opportunity to contribute from home in the validation of novel #eCOA. Discover more about the study here 👇 https://hubs.li/Q02NMtX80

"When I started Pip Hare Ocean Racing, I not only wanted to raise my own performance and create a British based high-performing team but I wanted to leave change behind me to make it easier for others to follow a pathway into the sport." In 2020, we teamed up with Aparito - a wholly owned subsidiary of Eli Lilly and Company to track physical and mental health data during the three months it took Pip to race around the world in the Vendée Globe. The ground breaking research looked at Pip's heart rate, calorie intake, sleep patterns and cognitive function, and after a lot of hard work the research has now been published! Read more here 👉 https://lnkd.in/dEMv2GtD

There's only one month left to claim your free ticket to our 10th anniversary! 🎆 🗓️ 15 October 2024 🕛 12:00 until 17:00 BST 📍 The British Museum, London We'll reveal our agenda and speakers over the coming weeks. 👀 Tickets are available here until 30 September 👇 https://hubs.li/Q02M_Mtx0 #Aparito10

Welcome to the team, Tatti. What job title should we give her? We're thinking Head of Pawsitivity... 🐶

📗New paper alert! 📗 In "Digital endpoints in clinical trials: emerging themes from a multi-stakeholder Knowledge Exchange event" the authors discuss how digital technologies can enable the decentralisation of #ClinicalTrials. 📚 Background Digital technologies, such as wearable devices and smartphone applications (apps), can enable the decentralisation of clinical trials by measuring endpoints in people’s chosen locations rather than in traditional clinical settings. Digital endpoints can allow high-frequency and sensitive measurements of health outcomes compared to visit-based endpoints which provide an episodic snapshot of a person’s health. However, there are underexplored challenges in this emerging space that require interdisciplinary and cross-sector collaboration. A multi-stakeholder Knowledge Exchange event was organised to facilitate conversations across silos within this research ecosystem. 👩🏽🔬Methods A survey was sent to an initial list of stakeholders to identify potential discussion topics. Additional stakeholders were identified through iterative discussions on perspectives that needed representation. Co-design meetings with attendees were held to discuss the scope, format and ethos of the event. The event itself featured a cross-disciplinary selection of talks, a panel discussion, small-group discussions facilitated via a rolling seating plan and audience participation via Slido. A transcript was generated from the day, which, together with the output from Slido, provided a record of the day’s discussions. Finally, meetings were held following the event to identify the key challenges for digital endpoints which emerged and reflections and recommendations for dissemination. 📊 Results Several challenges for digital endpoints were identified in the following areas: patient adherence and acceptability; algorithms and software for devices; design, analysis and conduct of clinical trials with digital endpoints; the environmental impact of digital endpoints; and the need for ongoing ethical support. Learnings taken for next generation events include the need to include additional stakeholder perspectives, such as those of funders and regulators, and the need for additional resources and facilitation to allow patient and public contributors to engage meaningfully during the event. Read the paper in full here 👇 https://hubs.li/Q02Kbg280

Thanks to Development Bank of Wales and all others that supported us along the way. Too many to list all here. It’s been an epic adventure over the last 10 years. I’m now looking forward to the new opportunities of digitising clinical trials and all things #eCOA as part of Eli Lilly and Company